Activity of oxaliplatin in patients with relapsed or cisplatin-refractory germ cell cancer: A study of the German Testicular Cancer Study Group

Journal of Clinical Oncology

Volumn 20, Issue 8, 2002, Pages 2031-2037

  Kollmannsberger, C ^{a,b,c,d,e,f,g,h,i,j}   Rick, O ^{a,b,c,d,e,f,g,h,i,j}   Derigs, H G ^{a,b,c,d,e,f,g,h,i,j}   Schleucher, N ^{a,b,c,d,e,f,g,h,i,j}   Schoffski P ^{a,b,c,d,e,f,g,h,i,j}   Beyer, J ^{a,b,c,d,e,f,g,h,i,j}   Schoch, R ^{a,b,c,d,e,f,g,h,i,j}   Sayer, H G ^{a,b,c,d,e,f,g,h,i,j}   Gerl, A ^{a,b,c,d,e,f,g,h,i,j}   Kuczyk, M ^{a,b,c,d,e,f,g,h,i,j}   Spott, C ^{a,b,c,d,e,f,g,h,i,j}   Kanz, L ^{a,b,c,d,e,f,g,h,i,j}   Bokemeyer, C ^{a,b,c,d,e,f,g,h,i,j}  

^a UNIVERSITY HOSPITAL TÜBINGEN   (Germany)

^b HUMBOLDT UNIVERSITY   (Germany)

^c JOHANNES GUTENBERG UNIVERSITY   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

^e PHILIPPS UNIVERSITY MARBURG   (Germany)

^f UNIVERSITY OF KIEL   (Germany)

^g FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^h UNIVERSITY OF MUNICH   (Germany)

ⁱ UNIVERSITY HOSPITAL ESSEN   (Germany)

^j LEIBNIZ UNIVERSITY HANNOVER   (Germany)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA FETOPROTEIN; BLEOMYCIN; CHORIONIC GONADOTROPIN BETA SUBUNIT; CISPLATIN; DEXAMETHASONE; ETOPOSIDE; IFOSFAMIDE; OXALIPLATIN; PACLITAXEL; SEROTONIN 3 ANTAGONIST; VINBLASTINE;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; CANCER RECURRENCE; CHEMOTHERAPY INDUCED EMESIS; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; FEVER; GERM CELL TUMOR; GRANULOCYTOPENIA; HUMAN; MALE; MUCOSA INFLAMMATION; NAUSEA; NEUROTOXICITY; PRIORITY JOURNAL; TESTIS CANCER; THROMBOCYTOPENIA;

EID: 0037089634     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2002.08.050     Document Type: Article

References (41)

1. Medical progress: Testicular germ-cell cancer
2. Treatment of testicular cancer: A new and improved model
3. Salvage treatment with paclitaxel, ifosfamide, and cisplatin plus high-dose carboplatin, etoposide, and thiotepa followed by autologous stem cell rescue in patients with relapsed or refractory germ cell cancer
4. Dose escalation study of high-dose carboplatin and etoposide with autologous bone marrow support in patients with recurrent and refractory germ cell tumors
5. High-dose carboplatin, etoposide, and cyclophosphamide for patients with refractory germ cell tumors: Treatment results and prognostic factors for survival and toxicity
6. Salvage chemotherapy for recurrent germ cell cancer
7. Results of treatment after relapse from high-dose chemotherapy in germ cell tumors
8. Phase II trial of topotecan in patients with cisplatin-refractory germ cell tumors
9. Ifosfamide in refractory male germ cell tumors
10. Treatment of relapsed nonseminoma germ cell tumors with vinorelbine: A trial of the phase I/II study group of the Association of Medical Oncology of the German Cancer Society
11. Phase II evaluation of iproplatin in refractory germ cell tumors: A Southeastern Cancer Study Group trial
12. Phase II study of iproplatin (CHIP) in patients with cisplatin-refractory germ cell tumors: The need for alternative strategies in the investigation of new agents in GCT
13. Phase II study of paclitaxel in patients with relapsed or cisplatin-refractory testicular cancer
14. Phase II trial of paclitaxel shows antitumor activity in patients with previously treated germ cell tumors
15. Phase II study of bendamustine in patients with relapsed or cisplatin-refractory germ cell cancer
16. Gemcitabine in patients with relapsed or cisplatin-refractory testicular cancer
17. Phase II trial of gemcitabine in refractory germ cell tumors
18. Phase II study of daily oral etoposide in refractory germ cell tumors
19. Paclitaxel, ifosfamide, and cisplatin second-line therapy for patients with relapsed testicular germ cell cancer
20. Management of intermediate prognosis germ cell cancer: Results of a phase I/II study of Taxol-BEP
21. Oxaliplatin (LOHP): Global safety in 682 patients
22. The role of DNA mismatch repair in platinum drug resistance
23. Comparative cytotoxicity of oxaliplatin and cisplatin in non-seminomatous germ cell lines
24. Weekly high-dose (HD) 5-fluorouracil (5-FU) and folic acid (FA) with addition of oxaliplatin (LOHP) after documented progression under high-dose infusional 5-FU/FA in patients (pts) with advanced colorectal cancer (CRC): A preliminary report
25. Activity of oxaliplatin against human tumor colony-forming units
26. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer
27. High-dose intensity oxaliplatin added to the simplified bimonthly leucovorin and 5-fluorouracil regimen as second-line therapy for metastatic colorectal cancer (FOLFOX 7)
28. Dose-intensive chemotherapy in refractory germ cell cancer: A phase I/II trial of high-dose carboplatin and etoposide with autologous bone marrow transplantation
29. High-dose chemotherapy as salvage treatment in germ cell tumors: A multivariate analysis of prognostic variables
30. Reporting results of cancer treatment
31. VP- 16 as a single agent in advanced testicular tumors
32. Oxaliplatin: A review of preclinical and clinical studies
33. Evaluation of novel platinum complexes, inhibitors of topoisomerase I and II in non-small cell lung cancer (NSCLC) sublines resistant to cisplatin
34. Oxaliplatin, tetraplatin, cisplatin, and carboplatin: Spectrum of activity in drug-resistant cell lines and in the cell lines of the National Cancer Institute's Anticancer Drug Screen panel
35. Oxaliplatin in ovarian cancer
36. Supraadditive effect of 2′,2′-difluorodeoxycytidine (gemcitabine) in combination with oxaliplatin in human cancer cell lines
37. Phase I study of the gemcitabine/oxaliplatin combination in patients with advanced solid tumors: A preliminary report
38. Final results of the phase I-II and pharmacokinetic study GEM/OX combining gemcitabine (GEM) with oxaliplatin (OX) in patients (pts) with advanced non-small cell lung (NSCLC) and ovarian carcinoma (OC)
39. Multicentric phase II-III trial of oxaliplatin (LOHP) versus cisplatin (P) both in association with cyclophosphamide (C) in the treatment of advanced ovarian cancer (AOC): Toxicity efficacy results
40. Oxaliplatin and paclitaxel combination in patients with platinum-pretreated ovarian carcinoma: An investigator-originated compassionate-use experience
41. Phase II trial of paclitaxel and gemcitabine in refractory germ cell tumors